During the past decade, FSBI NMRC PN n.a. V.M. Bekhterev conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "FSBI NMRC PN n.a. V.M. Bekhterev" are "Schizophrenia" (4 trials), "Neuropsychiatric Symptoms Related to Neurodegenerative Disease" (2 trials), "Symptomatic Neurogenic Orthostatic Hypotension" (2 trials), "MSA" (1 trials) and "Parkinson's Disease (PD)" (1 trials). Many other conditions were trialed in "FSBI NMRC PN n.a. V.M. Bekhterev" in a lesser frequency.

Most popular intervention types in "FSBI NMRC PN n.a. V.M. Bekhterev" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Pimavanserin" (4 trials), "Placebo" (4 trials), "ampreloxetine" (2 trials), "Cariprazine" (1 trials) and "SEP-363856" (1 trials). Other intervention names were less common.

The vast majority of trials in "FSBI NMRC PN n.a. V.M. Bekhterev" are 8 trials for "All" genders.

Currently, there are NaN active trials in "FSBI NMRC PN n.a. V.M. Bekhterev". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in FSBI NMRC PN n.a. V.M. Bekhterev, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in FSBI NMRC PN n.a. V.M. Bekhterev, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".